Personalized immunosuppression in transplantation : role of biomarker monitoring and therapeutic drug monitoring

__Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring__ provides coverage of the various approaches to monitoring immunosuppressants in transplant patients, including the most recently developed biomarker monitoring methods, pharmacogenomics approaches, and traditional therapeutic drug monitoring. The book is written for pathologists, toxicologists, and transplant surgeons who are involved in the management of transplant patients, offering them in-depth coverage of the management of immunosuppressant therapy in transplant patients with the goal of maximum benefit from drug therapy and minimal risk of drug toxicity. This book also provides practical guidelines for managing immunosuppressant therapy, including the therapeutic ranges of various immunosuppressants, the pitfalls of methodologies used for determination of these immunosuppressants in whole blood or plasma, appropriate pharmacogenomics testing for organ transplant recipients, and when biomarker monitoring could be helpful. * Focuses on the personalized management of immunosuppression therapy in individual transplant patients * Presents information that applies to many areas, including gmass spectrometry, assay design, assay validation, clinical chemistry, and clinical pathology * Provides practical guidelines for the initial selection and subsequent modifications of immunosuppression therapy in individual transplant patients * Reviews the latest research in biomarker monitoring in personalizing immunosuppressant therapy, including potential new markers not currently used, but with great potential for future use * Explains how monitoring graft-derived, circulating, cell free DNA has shown promise in the early detection of transplant injury in liquid biopsy

Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring provides coverage of the various approaches to monitoring immunosuppressants in transplant patients, including the most recently developed biomarker monitoring methods, pharmacogenomics approaches, and traditional therapeutic drug monitoring.

The book is written for pathologists, toxicologists, and transplant surgeons who are involved in the management of transplant patients, offering them in-depth coverage of the management of immunosuppressant therapy in transplant patients with the goal of maximum benefit from drug therapy and minimal risk of drug toxicity.

This book also provides practical guidelines for managing immunosuppressant therapy, including the therapeutic ranges of various immunosuppressants, the pitfalls of methodologies used for determination of these immunosuppressants in whole blood or plasma, appropriate pharmacogenomics testing for organ transplant recipients, and when biomarker monitoring could be helpful.

• Focuses on the personalized management of immunosuppression therapy in individual transplant patients
• Presents information that applies to many areas, including gmass spectrometry, assay design, assay validation, clinical chemistry, and clinical pathology
• Provides practical guidelines for the initial selection and subsequent modifications of immunosuppression therapy in individual transplant patients
• Reviews the latest research in biomarker monitoring in personalizing immunosuppressant therapy, including potential new markers not currently used, but with great potential for future use
• Explains how monitoring graft-derived, circulating, cell free DNA has shown promise in the early detection of transplant injury in liquid biopsy

Content: Front-matter,Copyright,Preface,List of ContributorsEntitled to full textChapter 1 - Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring, Pages 1-27, Michael C. Milone Chapter 2 - Limitations of immunoassays used for therapeutic drug monitoring of immunosuppressants, Pages 29-56, Amitava Dasgupta Chapter 3 - Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants, Pages 57-81, Kamisha L. Johnson-Davis, Gwendolyn A. McMillin Chapter 4 - Monitoring free mycophenolic acid concentration: Is there any clinical advantage?, Pages 83-107, Amitava Dasgupta Chapter 5 - Pharmacogenomics aspect of immunosuppressant therapy, Pages 109-124, Loralie Langman, Teun van Gelder, Ron H.N. van Schaik Chapter 6 - Biomarker monitoring in immunosuppressant therapy: An overview, Pages 125-152, Maria Shipkova Chapter 7 - Graft-derived cell-free DNA as a marker of graft integrity after transplantation, Pages 153-176, Michael Oellerich, Julia Beck, Philipp Kanzow, Jessica Schmitz, Otto Kollmar, Philip D. Walson, Ekkehard Schütz Chapter 8 - Biomarkers of tolerance in kidney transplantation, Pages 177-197, Daniel Baron, Magali Giral, Sophie Brouard Chapter 9 - Intracellular concentrations of immunosuppressants, Pages 199-226, Heike Bittersohl, Werner Steimer Chapter 10 - Markers of lymphocyte activation and proliferation, Pages 227-257, Eberhard Wieland Chapter 11 - Monitoring calcineurin inhibitors response based on NFAT-regulated gene expression, Pages 259-290, Sara Bremer, Nils Tore Vethe, Stein Bergan Index, Pages 291-302